BNTX Dec 2025 135.000 put
| Previous close | 31.30 |
| Open | 31.30 |
| Bid | 34.20 |
| Ask | 37.00 |
| Strike | 135.00 |
| Expiry date | 2025-12-19 |
| Day's range | 31.30 - 31.30 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
BloombergBioNTech Cancer Drug Licensed From MediLink Faces FDA Delay
(Bloomberg) -- The Food and Drug Administration delayed a breast- and lung-cancer trial of an experimental treatment that BioNTech SE licensed from Chinese biotech MediLink Therapeutics Ltd., citing safety concerns.Most Read from BloombergFlesh-Eating Bacteria That Can Kill in Two Days Spreads in JapanS&P 500 Hits 30th Record of 2024 as Megacaps Rally: Markets WrapThese Are the World’s Most Expensive Cities for Expats in 2024Hedge Funds’ Secret Weapon to Fight the SEC Lives in TexasHow the US Mo
- Yahoo Finance Video
FDA considers updating COVID boosters, Novavax stock reacts
The US Food and Drug Administration (FDA) is set to vote on recommendations for updated COVID-19 booster shots as the KP.2 variant strain begins to spread across the US. Yahoo Finance Health Reporter Anjalee Khemlani joins Market Domination to discuss the impact this is having on vaccine makers, particularly Novavax (NVAX), whose stock has shot up in Monday's session. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Luke Carberry Mogan.
Globe NewswireInvestigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic non-small cell lung cancer treated with a combination of acasunlimab and pembrolizumab every six weeksData from this ongoing Phase 2 study to inform the planned pivotal Phase 3 trial, which is expected to start before the end of 2024 COPENHAGEN, Denmark, and MAINZ, Germany, June 1, 2024 — Genmab A/S (
